Bahrain Approves GSK's New COVID19 Treatment

Published June 3rd, 2021 - 12:00 GMT
Bahrain Approves GSK's New COVID19 Treatment
The decision to add "Sotrovimab" to Covid-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well a comprehensive review of GSK's clinical trials. (Shutterstock)

Bahrain's National Health Regulatory Authority (NHRA) has approved "Sotrovimab" for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of Covid-19.

The decision to add "Sotrovimab" to Covid-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well a comprehensive review of GSK's clinical trials, said a Bahrain News Agency report.
 
“Sotrovimab-VIR-7831” develops “monoclonal antibodies” and will be used to treat infected adults and adolescents with mild to moderate Covid-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalisation, NHRA said.
 
Safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalisation for more than 24 hours and a reduction in the number fatalities by 85%, when administered at an early stage of treatment.

Copyright 2021 Al Hilal Publishing and Marketing Group

You may also like

Subscribe

Sign up to our newsletter for exclusive updates and enhanced content